{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:42Z","timestamp":1790769342171,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":38,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_11","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:35:09Z","timestamp":1790764509000},"page":"173-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA\/RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing"],"prefix":"10.1007","author":[{"given":"Rintaro Iwata","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"e22187","DOI":"10.1002\/ddr.22187","volume":"85","author":"E Ers\u00f6z","year":"2024","unstructured":"Ers\u00f6z E, Demir-Dora D (2024) Unveiling the potential of antisense oligonucleotides: mechanisms, therapies, and safety insights. Drug Dev Res 85:e22187","journal-title":"Drug Dev Res"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Baker BF, Crooke RM, Liang X-H (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20:427\u2013453","journal-title":"Nat Rev Drug Discov"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","volume":"270","author":"J Kurreck","year":"2003","unstructured":"Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628\u20131644","journal-title":"Eur J Biochem"},{"key":"11_CR4","doi-asserted-by":"crossref","unstructured":"Seth PP, Swayze EE (2019) The medicinal chemistry of RNase H-activating antisense oligonucleotides. Adv Nucleic Acid Therapeut chapter 3, 32\u201361","DOI":"10.1039\/9781788015714-00032"},{"key":"11_CR5","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair JK, Willoughby JLS, Chan A et al (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136:16958\u201316961","journal-title":"J Am Chem Soc"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J et al (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796\u20138807","journal-title":"Nucleic Acids Res"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1038\/mtna.2016.26","volume":"5","author":"RZ Yu","year":"2016","unstructured":"Yu RZ, Graham MJ, Post N et al (2016) Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice. Mol Ther Nucleic Acids 5:e317","journal-title":"Mol Ther Nucleic Acids"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2016.02.007","volume":"226","author":"S Wada","year":"2016","unstructured":"Wada S, Yasuhara H, Wada F et al (2016) Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. J Control Release 226:57\u201365","journal-title":"J Control Release"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nature03121","volume":"432","author":"J Soutschek","year":"2004","unstructured":"Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173\u2013178","journal-title":"Nature"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1038\/mtna.2014.72","volume":"4","author":"T Nishina","year":"2015","unstructured":"Nishina T, Numata J, Nishina K et al (2015) Chimeric antisense oligonucleotide conjugated to \u03b1-tocopherol. Mol Ther Nucleic Acids 4:e220","journal-title":"Mol Ther Nucleic Acids"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/mt.2008.14","volume":"16","author":"K Nishina","year":"2008","unstructured":"Nishina K, Unno T, Uno Y et al (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of \u03b1-tocopherol. Mol Ther 16:734\u2013740","journal-title":"Mol Ther"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.bmcl.2004.07.018","volume":"14","author":"C Lorenz","year":"2004","unstructured":"Lorenz C, Hadwiger P, John M et al (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14:4975\u20134977","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.1021\/acs.jmedchem.0c00840","volume":"63","author":"M Nikan","year":"2020","unstructured":"Nikan M, Tanowitz M, Dwyer CA et al (2020) Targeted delivery of antisense oligonucleotides using neurotensin peptides. J Med Chem 63:8471\u20138484","journal-title":"J Med Chem"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1021\/acschembio.1c00652","volume":"17","author":"T Harumoto","year":"2022","unstructured":"Harumoto T, Iwai H, Tanigawa M et al (2022) Enhancement of gene knockdown on CD22-expressing cells by chemically modified glycan ligand-siRNA conjugates. ACS Chem Biol 17:292\u2013298","journal-title":"ACS Chem Biol"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1093\/nar\/gkac308","volume":"50","author":"K Uehara","year":"2022","unstructured":"Uehara K, Harumoto T, Makino A et al (2022) Targeted delivery to macrophages and dendritic cells by chemically modified mannose ligand-conjugated siRNA. Nucleic Acids Res 50:4840\u20134859","journal-title":"Nucleic Acids Res"},{"key":"11_CR16","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1248\/bpb.b20-00052","volume":"43","author":"W Liao","year":"2020","unstructured":"Liao W, Akahira S, Hara RI et al (2020) Enhanced immunostimulatory activity of CpG oligodeoxynucleotide by the combination of mannose modification and incorporation into nanostructured DNA. Biol Pharm Bull 43:1188\u20131195","journal-title":"Biol Pharm Bull"},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41587-024-02487-7","volume":"43","author":"C Wang","year":"2025","unstructured":"Wang C, Wang S, Xue Y, et al (2025) Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system. Nat Biotechnol 43:1783\u20131789","journal-title":"Nat Biotechnol"},{"key":"11_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8969","volume":"6","author":"K Nishina","year":"2015","unstructured":"Nishina K, Piao W, Yoshida-Tanaka K et al (2015) DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun 6: 7969","journal-title":"Nat Commun"},{"key":"11_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26902-8","volume":"12","author":"M Ohyagi","year":"2021","unstructured":"Ohyagi M, Nagata T, Ihara K et al (2021) DNA\/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo. Nat Commun 12: 7344","journal-title":"Nat Commun"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.omtn.2022.05.006","volume":"28","author":"H Kaburagi","year":"2022","unstructured":"Kaburagi H, Nagata T, Enomoto M et al (2022) Systemic DNA\/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve. Mol Ther Nucleic Acids 28:910\u2013919","journal-title":"Mol Ther Nucleic Acids"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2337\/db21-0918","volume":"71","author":"A Miyashita","year":"2022","unstructured":"Miyashita A, Kobayashi M, Ishibashi S et al (2022) The role of long noncoding RNA MALAT1 in diabetic polyneuropathy and the impact of its silencing in the dorsal root ganglion by a DNA\/RNA heteroduplex oligonucleotide. Diabetes 71:1299\u20131312","journal-title":"Diabetes"},{"key":"11_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22577-2","volume":"8","author":"H Kuwahara","year":"2018","unstructured":"Kuwahara H, Song J, Shimoura T et al (2018) Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo. Sci Rep 8: 4377","journal-title":"Sci Rep"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","volume":"39","author":"T Nagata","year":"2021","unstructured":"Nagata T, Dwyer CA, Yoshida-Tanaka K, et al (2021) Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. Nat Biotechnol 39:1529\u20131536","journal-title":"Nat Biotechnol"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ymthe.2023.01.016","volume":"31","author":"F Li","year":"2023","unstructured":"Li F, Ichinose K, Ishibashi S et al (2023) Preferential delivery of lipid-ligand conjugated DNA\/RNA heteroduplex oligonucleotide to ischemic brain in hyperacute stage. Mol Ther 31:1106\u20131122","journal-title":"Mol Ther"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/j.ymthe.2022.02.019","volume":"30","author":"R Nishi","year":"2022","unstructured":"Nishi R, Ohyagi M, Nagata T et al (2022) Regulation of activated microglia and macrophages by systemically administered DNA\/RNA heteroduplex oligonucleotides. Mol Ther 30:2210\u20132223","journal-title":"Mol Ther"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/nar\/gky1260","volume":"47","author":"HJ Gaus","year":"2019","unstructured":"Gaus HJ, Gupta R, Chappell AE et al (2019) Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay. Nucleic Acids Res 47:1110\u20131122","journal-title":"Nucleic Acids Res"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.omtn.2024.102289","volume":"35","author":"M Ohara","year":"2024","unstructured":"Ohara M, Nagata T, Hara RI et al (2024) DNA\/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs. Mol Ther Nucleic Acids 35:102289","journal-title":"Mol Ther Nucleic Acids"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"7456","DOI":"10.1021\/jacs.9b13524","volume":"142","author":"M Hyjek-Sk\u0142adanowska","year":"2020","unstructured":"Hyjek-Sk\u0142adanowska M, Vickers TA, Napi\u00f3rkowska A et al (2020) Origins of the increased affinity of phosphorothioate-modified therapeutic nucleic acids for proteins. J Am Chem Soc 142:7456\u20137468","journal-title":"J Am Chem Soc"},{"key":"11_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22161-8","volume":"8","author":"RI Hara","year":"2018","unstructured":"Hara RI, Hisada Y, Maeda Y et al (2018) Artificial cationic oligosaccharides for heteroduplex oligonucleotide-type drugs. Sci Rep 8: 4323","journal-title":"Sci Rep"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"11499","DOI":"10.1039\/C8CC90436G","volume":"54","author":"RI Hara","year":"2018","unstructured":"Hara RI, Maeda Y, Fujimaki H, Wada T (2018) Enhancement in RNase H activity of a DNA\/RNA hybrid duplex using artificial cationic oligopeptides. Chem Commun 54:11499\u201311499","journal-title":"Chem Commun"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1021\/jo200951p","volume":"76","author":"R Iwata","year":"2011","unstructured":"Iwata R, Sudo M, Nagafuji K, Wada T (2011) Synthesis of oligodiaminosaccharides having \u03b1-glycoside bonds and their interactions with oligonucleotide duplexes. J Org Chem 76:5895\u20135906","journal-title":"J Org Chem"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1039\/C6OB02690G","volume":"15","author":"RI Hara","year":"2017","unstructured":"Hara RI, Maeda Y, Sakamoto T, Wada T (2017) Double-stranded RNA-binding artificial cationic oligosaccharides stabilizing siRNAs with a low N\/P ratio. Org Biomol Chem 15:1710\u20131717","journal-title":"Org Biomol Chem"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"e100951","DOI":"10.1371\/journal.pone.0100951","volume":"9","author":"DJ Hogan","year":"2014","unstructured":"Hogan DJ, Vincent TM, Fish S et al (2014) Anti-miRs competitively inhibit microRNAs in argonaute complexes. PLoS One 9:e100951","journal-title":"PLoS One"},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrd4359","volume":"13","author":"Z Li","year":"2014","unstructured":"Li Z, Rana TM (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13:622\u2013638","journal-title":"Nat Rev Drug Discov"},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1093\/nar\/gkz492","volume":"47","author":"K Yoshioka","year":"2019","unstructured":"Yoshioka K, Kunieda T, Asami Y et al (2019) Highly efficient silencing of microRNA by heteroduplex oligonucleotides. Nucleic Acids Res 47:7321\u20137332","journal-title":"Nucleic Acids Res"},{"key":"11_CR36","doi-asserted-by":"crossref","unstructured":"Nishina K, Yoshioka K, Yokota T, Hara RI (2024) Comparison of interaction between antimiR and microRNA versus HDO-antimiR and microRNA by molecular dynamics simulation. Nucleos Nucleot Nucl Acids 935\u2013950","DOI":"10.1080\/15257770.2024.2302526"},{"key":"11_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-48204-5","volume":"15","author":"J Hasegawa","year":"2024","unstructured":"Hasegawa J, Nagata T, Ihara K et al (2024) Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model. Nat Commun 15:1\u201315","journal-title":"Nat Commun"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.ymthe.2020.10.017","volume":"29","author":"Y Asami","year":"2021","unstructured":"Asami Y, Nagata T, Yoshioka K et al (2021) Efficient gene suppression by DNA\/DNA double-stranded oligonucleotide in vivo. Mol Ther 29:838\u2013847","journal-title":"Mol Ther"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:03:09Z","timestamp":1790766189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":38,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}